TrialsgrambetaRCTs are beautiful

ATTRibute-CM

2024

Efficacy and Safety of Acoramidis (AG10) in Subjects With Transthyretin Amyloid Cardiomyopathy

In 632 patients with transthyretin amyloid cardiomyopathy, acoramidis improved a hierarchical composite of death, CV hospitalisation, NT-proBNP and 6-minute walk distance compared with placebo.

Result

Efficacy: Hierarchical composite (all-cause death, CV hospitalisation, NT-proBNP, 6-minute walk) at 30 monthswin ratio 1.8 (95% CI 1.4-2.2) · P < 0.001

Below 1 favours placebo, above 1 favours acoramidis.

Also reported: Acoramidis superior on the hierarchical primary endpoint , driven largely by mortality and CV hospitalisation.

Original publication
Subtopic
TTR stabiliser
Design
Double-blind placebo-controlled RCT, phase 3
Relevance
Supporting: context rather than must-know.
Source
Gillmore JD, et al. N Engl J Med. 2024;390(2):132-142.doi 10.1056/NEJMoa2305434

Discussion & critique

Win-ratio composite harder to interpret clinically than event rates, and high background tafamidis use complicates comparison. Expanded disease-modifying options for ATTR-CM as a second-generation TTR stabiliser.

Discussed in podcasts